# Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypertension

> **NCT01131546** · PHASE4 · COMPLETED · sponsor: **Jiangsu Simcere Pharmaceutical Co., Ltd.** · enrollment: 1080 (estimated)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Levamlodipine besylate
- **DRUG:** Amlodipine maleate

## Key facts

- **NCT ID:** NCT01131546
- **Lead sponsor:** Jiangsu Simcere Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 1080 (ESTIMATED)
- **Last updated:** 2011-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01131546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01131546, "Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypertension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01131546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*